• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用地塞米松、瑞德西韦和恢复期血浆治疗 COVID-19 急性严重低氧性呼吸衰竭:固有决心行动中的首例病例报告。

Treating COVID-19 Acute Severe Hypoxemic Respiratory Failure: First Case Report Utilizing Dexamethasone, Remdesivir, and Convalescent Plasma in Operation Inherent Resolve.

机构信息

Department of Family Medicine, Thomas Moore Health Clinic, Fort Hood, TX.

Department of Emergency Medicine at Brook Army Medical Center, Fort Sam Houston, TX.

出版信息

Med J (Ft Sam Houst Tex). 2021 Jan-Mar(PB 8-21-01/02/03):28-33.

PMID:33666909
Abstract

Coronavirus 2019 (COVID-19) has spread across the globe with a concerningly high infectivity resulting in the World Health Organization deeming it a pandemic. It has resulted in thousands of deaths and placed enormous strain on communities, healthcare systems and healthcare workers as they battle shortages of ventilators, supplies, and difficulties in protecting patients and hospital staff alike. Challenges in managing the disease have led to new treatment and management strategies as healthcare teams struggle to adapt. We present the first case of COVID-19 managed in the austere deployed environment of Operation Inherent Resolve in which the patient was treated with dexamethasone, remdesivir, COVID-19 convalescent plasma, positive pressure ventilation, and proning. We discuss some of the inherent and unique challenges of caring for a patient in this resource constrained environment with a brief review of the literature on the treatment and management.

摘要

2019 年冠状病毒(COVID-19)在全球范围内迅速传播,其传染性令人担忧,世界卫生组织(World Health Organization)已将其宣布为大流行。它导致了数千人死亡,并给社区、医疗保健系统和医疗保健工作者带来了巨大压力,因为他们面临着呼吸机、用品短缺以及难以保护患者和医院工作人员的问题。管理这种疾病的挑战导致了新的治疗和管理策略,因为医疗团队努力适应。我们报告了首例在“坚定决心行动”(Operation Inherent Resolve)部署环境中管理的 COVID-19 病例,该患者接受了地塞米松、瑞德西韦、COVID-19 恢复期血浆、正压通气和俯卧位通气治疗。我们讨论了在这种资源有限的环境中照顾患者所面临的一些固有和独特的挑战,并简要回顾了关于治疗和管理的文献。

相似文献

1
Treating COVID-19 Acute Severe Hypoxemic Respiratory Failure: First Case Report Utilizing Dexamethasone, Remdesivir, and Convalescent Plasma in Operation Inherent Resolve.利用地塞米松、瑞德西韦和恢复期血浆治疗 COVID-19 急性严重低氧性呼吸衰竭:固有决心行动中的首例病例报告。
Med J (Ft Sam Houst Tex). 2021 Jan-Mar(PB 8-21-01/02/03):28-33.
2
Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma.瑞德西韦和 2019 冠状病毒病恢复期血浆治疗的新生儿重症急性呼吸综合征冠状病毒 2 型肺炎。
J Pediatric Infect Dis Soc. 2021 May 28;10(5):691-694. doi: 10.1093/jpids/piaa165.
3
Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).新冠病毒疾病药物治疗最大规模临床试验的当前进展洞察(截至2021年1月)
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2021 Apr 23;42(1):5-18. doi: 10.2478/prilozi-2021-0001.
4
Treatment of COVID-19: a review of current and prospective pharmacotherapies.治疗 COVID-19:当前和潜在药物疗法综述。
Br J Hosp Med (Lond). 2021 Mar 2;82(3):1-9. doi: 10.12968/hmed.2021.0112. Epub 2021 Mar 12.
5
Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients.瑞德西韦与高滴度康复期血浆联合用于COVID-19感染血液病患者的早期治疗取得成功。
Hematol Oncol. 2021 Dec;39(5):715-720. doi: 10.1002/hon.2908. Epub 2021 Aug 16.
6
Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study.羟氯喹、瑞德西韦和地塞米松在美国 COVID-19 住院成人患者中的使用:一项回顾性队列研究。
Ann Intern Med. 2021 Oct;174(10):1395-1403. doi: 10.7326/M21-0857. Epub 2021 Aug 17.
7
A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma.一名患有X连锁无丙种球蛋白血症且感染新冠病毒的患者接受瑞德西韦和康复期血浆治疗。
J Clin Immunol. 2021 Jul;41(5):923-925. doi: 10.1007/s10875-021-00983-y. Epub 2021 Feb 6.
8
Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update.《拯救脓毒症运动:成人 ICU 中 2019 年冠状病毒病(COVID-19)管理指南》:第一版更新。
Crit Care Med. 2021 Mar 1;49(3):e219-e234. doi: 10.1097/CCM.0000000000004899.
9
Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak.针对 COVID-19 的治疗和疫苗选择:疾病爆发六个月后的现状。
SLAS Discov. 2021 Mar;26(3):311-329. doi: 10.1177/2472555220979579. Epub 2020 Dec 15.
10
COVID-19, a tale of two peaks: patients' characteristics, treatments, and clinical outcomes.COVID-19,双峰之见:患者特征、治疗方法和临床结局。
Intern Emerg Med. 2021 Sep;16(6):1629-1639. doi: 10.1007/s11739-021-02711-1. Epub 2021 Apr 1.

引用本文的文献

1
Elizabethkingia meningoseptica Infection in COVID-19 Patients.新冠肺炎患者感染脑膜败血伊丽莎白金菌
Cureus. 2022 Oct 15;14(10):e30337. doi: 10.7759/cureus.30337. eCollection 2022 Oct.